Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gujarat Themis BiosynBOM:506879 -0.20%76 Days Payable is 682.50 as of Mar. 2026, which is 363% above its 10-year median of 147.26. GuruFocus rates BOM:506879 with a GF Score™ of 76/100 and a GF Value™ of ₹313.47 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 927 Drug Manufacturers companies, Gujarat Themis Biosyn ranks better than 92.02% on this metric.
The historical rank and industry rank for Gujarat Themis Biosyn's Days Payable or its related term are showing as below:
BOM:506879'
s Days Payable Range Over the Past 10 Years
Min: 85.32 Med: 147.26 Max: 567.26
Current: 357.61
During the past 13 years, Gujarat Themis Biosyn's highest Days Payable was 567.26. The lowest was 85.32. And the median was 147.26.
BOM:506879's Days Payable is ranked better than 92.02% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:506879: 357.61
Gujarat Themis Biosyn Days Payable Historical Data
* Premium members only.
The historical data trend for Gujarat Themis Biosyn's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Gujarat Themis Biosyn's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gujarat Themis Biosyn Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gujarat Themis Biosyn's Days Payable distribution charts can be found below:
* The bar in red indicates where Gujarat Themis Biosyn's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Gujarat Themis Biosyn's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gujarat Themis Biosyn (BOM:506879) has a Days Payable of 682.50 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gujarat Themis Biosyn and its competitors. This is 363% above median its historical median of 147.26. Over the past decade, Gujarat Themis Biosyn's Days Payable has ranged from 85.32 to 567.26. According to the industry distribution chart, Gujarat Themis Biosyn ranks #74 out of 927 companies in the Drug Manufacturers industry, placing it in the top 8%.
Is Gujarat Themis Biosyn's Days Payable too high?
Gujarat Themis Biosyn's current Days Payable of 682.50 is 363% above median its 10-year median of 147.26. Over the past 10 years, this metric has ranged from a low of 85.32 to a high of 567.26. The Drug Manufacturers industry median Days Payable is 90.38. Gujarat Themis Biosyn's value of 682.50 is 655.1% above this industry median. Based on the distribution chart, Gujarat Themis Biosyn ranks #74 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Gujarat Themis Biosyn has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gujarat Themis Biosyn's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gujarat Themis Biosyn ranks #74 out of 927 companies for Days Payable. This places Gujarat Themis Biosyn in the top 8% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Gujarat Themis Biosyn's value of 682.50 is 655.1% above this benchmark. Historically, Gujarat Themis Biosyn's own Days Payable has ranged from 85.32 to 567.26 over the past decade. While the company's 10-year median is 147.26 vs. the industry median of 90.38, Gujarat Themis Biosyn has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gujarat Themis Biosyn's current Days Payable of 682.50 is 655.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gujarat Themis Biosyn and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Themis Biosyn's current Days Payable is 682.50, which is 363% above median its own 10-year median of 147.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Themis Biosyn stock overvalued right now?
Based on GuruFocus' analysis, Gujarat Themis Biosyn (BOM:506879) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹313.47, compared to a current price of ₹370.90 — trading 18.3% above its estimated fair value. The current Days Payable is 682.50, which is 363% above median its 10-year median of 147.26 and 655.1% above the Drug Manufacturers industry median of 90.38. Gujarat Themis Biosyn's overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Gujarat Themis Biosyn (BOM:506879), the current Days Payable is 682.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gujarat Themis Biosyn (BOM:506879) Overvalued in 2026?
Based on GuruFocus' analysis, Gujarat Themis Biosyn stock appears to be overvalued.
The current stock price of ₹370.90 is trading 18.3% above its estimated GF Value™ of ₹313.47.
GuruFocus considers Gujarat Themis Biosyn to be Modestly Overvalued.
Key valuation signals for BOM:506879:
Days Payable: 682.50 (363% above median its 10-year median of 147.26)
GF Value™: ₹313.47 vs. price of ₹370.90 (18.3% above fair value)
Industry Position: 655.1% above the Drug Manufacturers median (#74 of 927)
No single metric tells the full story. See the BOM:506879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gujarat Themis Biosyn Ltd is engaged in manufacturing, exporting, and selling of bulk drugs on a job-work basis. The company operates in one segment which is pharmaceuticals. Its products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
76GF Score
Get the complete analysis for BOM:506879
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506879 has been successfully added to your 
